548 results on '"Muhlestein, Joseph B."'
Search Results
2. Intermittent fasting and changes in clinical risk scores: Secondary analysis of a randomized controlled trial
3. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results.
4. Impact of Statin Therapy in Heart Failure Patients: Results of a Large Real-World Experience
5. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.
6. Abstract 15447: The Association of Maternal Statin Use During Pregnancy to Perinatal Outcomes
7. Abstract 14841: Higher Than Daily RDA Recommended Vitamin D3 Dosing and Multiple Titrations Are Required to Achieve >40 ng/mL 25-hydroxy Vitamin D Levels in Acute Coronary Syndrome (ACS) Participants Enrolled and Randomized to Targeted Vitamin D Treatment: The Target D Trial
8. Abstract 13308: Characteristics of Participants Enrolled in a Randomized Controlled Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events: The Target-D Trial
9. Spectrum of radionuclide perfusion study abnormalities in takotsubo cardiomyopathy
10. Intermittent fasting and changes in Galectin-3: A secondary analysis of a randomized controlled trial of disease-free subjects
11. Insulin Growth Factor Phenotypes in Heart Failure With Preserved Ejection Fraction, an INSPIRE Registry and CATHGEN Study
12. Real-world clinical burden and economic assessment associated with hyperkalaemia in a large integrated healthcare system: a retrospective analysis
13. Coronary Artery Calcium Versus Pooled Cohort Equations Score for Primary Prevention Guidance: Randomized Feasibility Trial
14. Behavioral Nudges as Patient Decision Support for Medication Adherence: The ENCOURAGE Randomized Controlled Trial
15. Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery disease
16. Weight Loss-Independent Changes in Human Growth Hormone During Water-Only Fasting: A Secondary Evaluation of a Randomized Controlled Trial
17. Contemporary Predictors of Major Adverse Cardiovascular Events following Percutaneous Coronary Intervention: A Nationally Representative US Sample
18. Simplifying the ISCHEMIA trial algorithm for clinical practice: Identifying left main coronary artery disease using coronary artery calcium scans
19. Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation
20. Abstract 12870: Absence of LDL Measurement in Secondary Prevention is Associated With Increased Subsequent Major Adverse Clinical Event (MACE) That is Only Partially Mitigated by Statin Use
21. Abstract 12122: Five-Year Serial Measurement of the Intermountain Mortality Risk Score for Population Health Assessment Reveals Personalized Temporal Trajectories of Differential Longevity Over Two Decades
22. Abstract 11652: What is the Relative Risk for Elevated Liver Function Tests of Single and Combined Statin and Alcohol Use and Implications for Management?
23. Abstract 11600: Characteristics and Outcomes of Statin Use During Pregnancy: A US Real-World Experience
24. Abstract 10842: Progression of COVID-19 Severity Among SARS-CoV-2 Positive Patients Prescribed Selective Serotonin Reuptake Inhibitors
25. Abstract 10714: Disparities in Cardiovascular Investigator-Initiated Research Studies
26. Abstract 10149: Clinical Predictors of Medical Therapy-Induced Improvement in Left Ventricular Function in Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HFrEF): The Intermountain Healthcare Experience
27. Abstract 10083: Cardiovascular Outcomes of Non-ST-Elevation Myocardial Infarction (NSTEMI) Patients Without Standard Modifiable Risk Factors (SMuRF-less): The Intermountain Healthcare Experience
28. Discovery of TITIN Gene Truncating Variant Mutations and 5-Year Outcomes in Patients With Nonischemic Dilated Cardiomyopathy
29. Intermountain chronic disease risk score (ICHRON) validation for prediction of incident chronic disease diagnoses in an australian primary prevention population
30. Comparison of Three Atherosclerotic Cardiovascular Disease Risk Scores With and Without Coronary Calcium for Predicting Revascularization and Major Adverse Coronary Events in Symptomatic Patients Undergoing Positron Emission Tomography-Stress Testing
31. Clinicoeconomic Burden of Heart Failure Patients with Severely Reduced Ejection Fraction HF-RESTORE
32. A genome-wide meta-analysis uncovers six sequence variants conferring risk of vertigo
33. Circulating Levels of Biomarkers of Cerebral Injury in Patients with Atrial Fibrillation
34. Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study
35. Safety and Efficacy of Periprocedural Heparin Plus a Short-Term Infusion of Tirofiban Versus Bivalirudin Monotherapy in Patients Who Underwent Percutaneous Coronary Intervention (from the Intermountain Heart Institute STAIR Observational Registry)
36. Abstract 14841: Higher Than Daily RDA Recommended Vitamin D 3 Dosing and Multiple Titrations Are Required to Achieve >40 ng/mL 25-hydroxy Vitamin D Levels in Acute Coronary Syndrome (ACS) Participants Enrolled and Randomized to Targeted Vitamin D Treatment: The Target D Trial
37. Temporal changes in statin prescription and intensity at discharge and impact on outcomes in patients with newly diagnosed atherosclerotic cardiovascular disease—Real-world experience within a large integrated health care system: The IMPRES study
38. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study
39. Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial
40. The role of microRNAs in the development, regulation, and treatment of atrial fibrillation
41. Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 Studies
42. Higher docosahexaenoic acid levels lower the protective impact of eicosapentaenoic acid on long-term major cardiovascular events
43. Quantitative imaging biomarkers of coronary plaque morphology: insights from EVAPORATE
44. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study
45. Abstract 16802: Economics and Outcomes of Sotalol and Dofetilide In-Patient Dosing Approaches in Patients With Atrial Fibrillation
46. Abstract 16745: Effect of the Baseline Use of Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin-Receptor Blockers (ARBs) on Outcomes of Patients With Suspected or Positive COVID-19 Infection
47. Abstract 16681: Ability of the Intermountain Risk Score Measured in 2019 (pre-COVID) to Predict Major Adverse Health Events in Patients Positive for SARS-CoV-2 in 2020
48. Abstract 16587: More Than Five Years After FDA Approval, There Remains Very Limited Adoption of New Evidence-Based, Highly Effective Medications for the Treatment of Patients With Heart Failure, Especially Among Those on Medicare
49. Abstract 15941: Derivation of Risk-Scores That Stratify Risk of Hospitalization and Death in SARS-CoV-2 Positive Patients
50. Abstract 15875: Prediction of Intensive Care Unit Admission Among Patients Hospitalized for COVID-19: The Intermountain Coronavirus ICU Risk Model (CORONA-ICU)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.